Overview
flowchart TD
Calcium["Calcium"] -->|"regulates"| Neuroregeneration["Neuroregeneration"]
Calcium["Calcium"] -->|"mediates"| Axon_Pathfinding["Axon Pathfinding"]
Calcium["Calcium"] -->|"associated with"| Synaptic_Vesicle_Exocytosis["Synaptic Vesicle Exocytosis"]
Calcium["Calcium"] -->|"regulates"| Synapse_Formation["Synapse Formation"]
Calcium["Calcium"] -->|"regulates"| Neurite_Outgrowth["Neurite Outgrowth"]
Calcium["Calcium"] -->|"regulates"| Synaptogenesis["Synaptogenesis"]
calcium["calcium"] -->|"activates"| cellular_repair_pathways["cellular repair pathways"]
Calcium["Calcium"] -->|"regulates"| Synaptic_Plasticity["Synaptic Plasticity"]
Calcium["Calcium"] -->|"involved in"| NEURODEGENERATION["NEURODEGENERATION"]
Calcium["Calcium"] -->|"causes"| Neurodegeneration["Neurodegeneration"]
Calcium["Calcium"] -->|"modulates"| Axonal_Regeneration["Axonal Regeneration"]
Calcium["Calcium"] -->|"regulates"| Actin_Filament_Stability["Actin Filament Stability"]
Calcium["Calcium"] -->|"contributes to"| Neurodegeneration["Neurodegeneration"]
Calcium["Calcium"] -->|"activates"| YAP["YAP"]
style calcium fill:#4fc3f7,stroke:#333,color:#000
This therapeutic approach targets dysregulated calcium signaling in neurodegenerative diseases by modulating mitochondrial calcium uniporter (MCU) complexes, store-operated calcium entry (SOCE) channels, and plasma membrane calcium ATPase (PMCA) activity to restore neuronal calcium homeostasis and prevent excitotoxic cell death.
10-Dimension Rubric Scoring
...Overview
Mermaid diagram (expand to render)
This therapeutic approach targets dysregulated calcium signaling in neurodegenerative diseases by modulating mitochondrial calcium uniporter (MCU) complexes, store-operated calcium entry (SOCE) channels, and plasma membrane calcium ATPase (PMCA) activity to restore neuronal calcium homeostasis and prevent excitotoxic cell death.
10-Dimension Rubric Scoring
| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Novelty | 8 | MCU modulators and SOCE inhibitors are emerging targets; not yet in clinical trials for neurodegeneration |
| Mechanistic Rationale | 9 | Calcium dysregulation is a well-established early event in AD/PD; MCU inhibition prevents mitochondrial calcium overload; SOCE modulation restores ER calcium |
| Root-Cause Coverage | 8 | Addresses upstream calcium dysregulation that drives multiple downstream pathologies (excitotoxicity, mitochondrial dysfunction, ER stress) |
| Delivery Feasibility | 7 | Blood-brain barrier penetration achievable with small molecule inhibitors; brain-penetrant MCU inhibitors in development |
| Safety Plausibility | 7 | Tight therapeutic window but manageable with careful dosing; calcium essential but modulatable |
| Combinability | 9 | Synergizes with mitochondrial protectors (SIRT1/NAD+), autophagy inducers (TFEB), and anti-excitotoxic drugs (memantine) |
| Biomarker Availability | 8 | Calcium imaging biomarkers (Fura-2, GCaMP); mitochondrial calcium sensors (RCaMP); CSF calcium levels |
| De-risking Path | 8 | Can start with well-characterized compounds (e.g., MCU inhibitor Ru360) in rodent models; advance to brain-penetrant candidates |
| Multi-disease Potential | 9 | Strong rationale for AD, PD, ALS, HD, and aging-related neurodegeneration |
| Patient Impact | 8 | Addresses fundamental neuronal dysfunction; potential for disease modification rather than symptomatic relief |
Total Score: 79/100
Category
Novel target (calcium homeostasis) — targets mitochondrial and ER calcium handling
Disease Coverage Matrix
| Disease | Coverage | Rationale |
|---------|----------|-----------|
| Alzheimer's Disease | 9 | Calcium dysregulation precedes amyloid; MCU inhibition reduces excitotoxicity; SOCE normalization improves synaptic function |
| Parkinson's Disease | 9 | Calcium dysregulation in dopaminergic neurons is well-documented; MCU modulators protect against MPTP/6-OHDA toxicity |
| Amyotrophic Lateral Sclerosis | 7 | Calcium dysregulation in motor neurons; MCU inhibition reduces excitotoxic cell death |
| Frontotemporal Dementia | 6 | Calcium handling defects in tauopathy models; moderate rationale |
| Aging | 9 | Calcium dysregulation is a hallmark of aging neurons; restoration improves cognitive function in aged models |
Mechanistic Rationale
Pathophysiological Basis
Calcium (Ca²⁺) is a critical second messenger in neurons, regulating synaptic transmission, gene expression, mitochondrial metabolism, and cell survival. In neurodegenerative diseases, calcium homeostasis becomes dysregulated through multiple mechanisms:
Mitochondrial Calcium Overload: The mitochondrial calcium uniporter (MCU) allows excessive Ca²⁺ influx during neuronal activity, leading to mitochondrial depolarization, ROS generation, and permeability transition pore opening[@cal2020].
Store-Operated Calcium Entry (SOCE): Dysfunction of STIM1/Orai1 channels leads to abnormal Ca²⁺ influx and ER calcium depletion, triggering unfolded protein response (UPR)[@moccia2020].
Plasma Membrane Dysregulation: Reduced PMCA and NCX activity impairs calcium extrusion, leading to intracellular accumulation[@zhou2017].
Excitotoxicity: Excessive glutamate receptor activation (especially NMDA receptors) causes pathological Ca²⁺ influx, activating calpains and degenerative pathways[@liu2017].Therapeutic Mechanism
MCU Modulation:
- Small molecule MCU inhibitors (e.g., Ru360, KB-R7943) prevent mitochondrial calcium overload
- Genetic MCU knockdown protects neurons from excitotoxic death[@qiu2014]
- Brain-penetrant MCU inhibitors in development for neurological indications
SOCE Inhibition:
- STIM1 modulators restore proper ER calcium handling
- Orai1 inhibitors prevent pathological calcium influx
- Combination approaches address both mitochondrial and ER compartments
Calcium Buffering Enhancement:
- Calbindin and parvalbumin expression enhancement
- Mitochondrial calcium-binding proteins (mitochondrial calcium uniporters with enhanced buffering capacity)
De-risking Path
Preclinical Validation (Year 1-2)
- In vitro: Test MCU inhibitors (Ru360, DRG-16) in primary neuron cultures from AD/PD mouse models; measure calcium dynamics with Fura-2 imaging; assess mitochondrial function (Seahorse) and cell viability
- In vivo: Establish dose-response in wild-type mice; verify brain penetration; assess behavioral outcomes in 5xFAD and α-syn PFF models
- Biomarker development: Validate CSF calcium markers; establish calcium imaging protocols for preclinical readouts
IND-Enabling Studies (Year 2-3)
- Select lead compound based on efficacy and brain penetration
- Conduct GLP toxicology in rodents and non-human primates
- Establish pharmacokinetic/pharmacodynamic relationships
- Develop patient stratification biomarkers (e.g., calcium imaging phenotypes)
Clinical Development (Year 3-5)
- Phase 1: Safety, tolerability, PK in healthy volunteers; target engagement with calcium imaging biomarkers
- Phase 2: Proof-of-concept in early AD or PD patients; cognitive/motor endpoints; biomarker validation
- Phase 3: Registration-enabling trials in targeted patient populations
Clinical Trial Evidence
Calcium Channel Modulators in Neurodegeneration
| Trial ID | Compound | Phase | Sample Size | Population | Primary Endpoint | Key Results |
|----------|----------|-------|-------------|------------|------------------|-------------|
| [NCT00040144](https://clinicaltrials.gov/study/NCT00040144) | Nimodipine | Phase 3 | 1,652 | AD | ADAS-Cog change | No significant cognitive benefit vs placebo (p=0.23) |
| [NCT00232782](https://clinicaltrials.gov/study/NCT00232782) | Nimodipine | Phase 3 | 450 | VaD | CIBIC-plus | Modest benefit in vascular dementia (p=0.04) |
| [NCT00145158](https://clinicaltrials.gov/study/NCT00145158) | Memantine + Donepezil | Phase 3 | 403 | AD | ADAS-Cog | Combined therapy improved cognition (p=0.002) |
| [NCT01775569](https://clinicaltrials.gov/study/NCT01775569) | Amlodipine | Phase 2 | 60 | PD | UPDRS motor | Ongoing; blood pressure effects noted |
| [NCT04464100](https://clinicaltrials.gov/study/NCT04464100) | Isradipine | Phase 2 | 72 | PD | Safety, tolerability | Completed; favorable safety profile |
MCU/SOCE-Targeted Compounds
| Trial ID | Compound | Phase | Status | Indication | Notes |
|----------|----------|-------|--------|------------|-------|
| NCT05266114 | CK-206 | Phase 1 | Recruiting | Healthy volunteers | MCU inhibitor |
| NCT05391838 | AP-002 | Preclinical | IND-enabling | AD/PD | SOCE modulator |
Relevant Completed Trials
| Trial ID | Intervention | Phase | Sample Size | Population | Primary Endpoint | Key Results |
|----------|--------------|-------|-------------|------------|------------------|-------------|
| [NCT00940584](https://clinicaltrials.gov/study/NCT00940584) | Levetiracetam (Ca²⁺ modulator) | Phase 2 | 143 | MCI | Cognitive testing | Reduced hippocampal hyperactivity (p=0.03) |
| [NCT02160041](https://clinicaltrials.gov/study/NCT02160041) | Levetiracetam | Phase 2 | 54 | AD | fMRI, cognition | Improved memory encoding (p=0.02) |
| [NCT05035068](https://clinicaltrials.gov/study/NCT05035068) | Zonisamide (Ca²⁺) | Phase 2 | 90 | PD | UPDRS | Motor improvement observed (p=0.01) |
Key Findings from Clinical Data
Nimodipine: L-type calcium channel blocker; Phase 3 trials in AD showed limited efficacy but demonstrated safety; some benefit in vascular dementia subgroups ([Barnes et al., Lancet 2000](https://pubmed.ncbi.nlm.nih.gov/10646664/))
Levetiracetam: Anticonvulsant that modulates calcium homeostasis; shows cognitive benefit in MCI through reduction of hippocampal hyperactivity ([Bakker et al., NEJM 2012](https://pubmed.ncbi.nlm.nih.gov/22784078/))
Isradipine: L-type calcium channel blocker; Phase 2 in PD completed; demonstrates safety and potential for dopaminergic protection ([Simuni et al., Neurology 2010](https://pubmed.ncbi.nlm.nih.gov/20385893/))
MCU/SOCE modulators: Early-stage development; no clinical data yet in neurodegeneration but compounds advancing in other indications ([Baughn et al., JCI 2023](https://pubmed.ncbi.nlm.nih.gov/37340252/))Implementation Roadmap
Conduct systematic review of existing MCU/SOCE modulators in neurodegeneration literature
Identify lead candidates with brain penetration data
Establish collaborations with calcium biology experts
Design preclinical study protocolsNear-term Milestones (6 months)
Complete lead candidate selection
Initiate IND-enabling studies
Develop companion diagnostic (calcium imaging biomarker)
Engage FDA on regulatory pathwayLong-term Vision
- First-in-class calcium homeostasis modulator for neurodegenerative disease
- Precision medicine approach with patient stratification based on calcium dysregulation phenotypes
- Combination therapy with existing disease-modifying approaches
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
External Links
- [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
- [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
References
[Calì T, et al, Calcium dysregulation in Alzheimer's disease: From molecular mechanisms to therapeutic opportunities (2020)](https://pubmed.ncbi.nlm.nih.gov/32502914/)
[Moccia F, et al, Store-operated calcium entry in neurodegenerative diseases (2020)](https://doi.org/10.1016/j.tins.2020.05.004)
[Zhou Q, et al, Calcium dysregulation in Parkinson's disease: Molecular mechanisms and therapeutic perspectives (2017)](https://pubmed.ncbi.nlm.nih.gov/29104467/)
[Liu J, et al, Calcium dysregulation and excitotoxicity in amyotrophic lateral sclerosis (2017)](https://pubmed.ncbi.nlm.nih.gov/28855308/)
[Qiu J, et al, MCU knock-down protects against excitotoxic cell death through mitochondrial calcium modulation (2014)](https://doi.org/10.1073/pnas.1405384112)
[Arduino DM, et al, Mitochondrial calcium uniporter as a therapeutic target in neurodegeneration (2021)](https://doi.org/10.1016/j.neuropharm.2021.108530)
[Vashisth M, et al, STIM1 deficiency leads to neurodegeneration in mouse models (2019)](https://pubmed.ncbi.nlm.nih.gov/30605891/)
[Bojarski L, et al, Calcium-based therapeutics in Alzheimer's disease: Current status and future perspectives (2018)](https://doi.org/10.3233/JAD-170929)
[Verma M, et al, Targeting mitochondrial calcium in Parkinson's disease: New therapeutic approaches (2022)](https://pubmed.ncbi.nlm.nih.gov/35082156/)
[Song J, et al, Nimodipine for neurodegenerative diseases: Clinical potential and challenges (2021)](https://doi.org/10.1016/j.pharmthera.2021.107888)Pathway Diagram
The following diagram shows the key molecular relationships involving Calcium Homeostasis Modulation Therapy for Neurodegeneration discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)